Data analytics company Origent Data Sciences has launched a collaboration with biotechnology company Cytokinetics to test its computational models on ALS clinical trial data. Origent, a winner of the ALS Prediction Prize4Life Challenge (see Nov 2012 news), has developed algorithms for patient-level prediction of disease progression in ALS and other neurodegenerative diseases, as a means to improve clinical trial design and efficiency. The collaboration with Cytokinetics will provide Origent with its first opportunity to prospectively validate its models, using clinical data derived from the ongoing Phase III trial of tirasemtiv in ALS (see July 2015 news). If validated, the results will be submitted to the FDA to potentially open the door for utilization of these approaches in ALS clinical trial design.
Click here to read more.